BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20935635)

  • 1. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.
    Chen S; Bohrer LR; Rai AN; Pan Y; Gan L; Zhou X; Bagchi A; Simon JA; Huang H
    Nat Cell Biol; 2010 Nov; 12(11):1108-14. PubMed ID: 20935635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.
    Zeng X; Chen S; Huang H
    Cell Cycle; 2011 Feb; 10(4):579-83. PubMed ID: 21278485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.
    Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC
    Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability.
    Wu SC; Zhang Y
    J Biol Chem; 2011 Aug; 286(32):28511-9. PubMed ID: 21659531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
    Balasubramanian S; Adhikary G; Eckert RL
    Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mallory-Denk bodies form when EZH2/H3K27me3 fails to methylate DNA in the nuclei of human and mice liver cells.
    French BA; Oliva J; Bardag-Gorce F; Li J; Zhong J; Buslon V; French SW
    Exp Mol Pathol; 2012 Jun; 92(3):318-26. PubMed ID: 22465358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
    Yang X; Karuturi RK; Sun F; Aau M; Yu K; Shao R; Miller LD; Tan PB; Yu Q
    PLoS One; 2009; 4(4):e5011. PubMed ID: 19340297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Polycomb group protein EZH2 directly controls DNA methylation.
    Viré E; Brenner C; Deplus R; Blanchon L; Fraga M; Didelot C; Morey L; Van Eynde A; Bernard D; Vanderwinden JM; Bollen M; Esteller M; Di Croce L; de Launoit Y; Fuks F
    Nature; 2006 Feb; 439(7078):871-4. PubMed ID: 16357870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.
    Friedman J; Cho WK; Chu CK; Keedy KS; Archin NM; Margolis DM; Karn J
    J Virol; 2011 Sep; 85(17):9078-89. PubMed ID: 21715480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
    Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA.
    Kaneko S; Li G; Son J; Xu CF; Margueron R; Neubert TA; Reinberg D
    Genes Dev; 2010 Dec; 24(23):2615-20. PubMed ID: 21123648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.
    Sarma K; Margueron R; Ivanov A; Pirrotta V; Reinberg D
    Mol Cell Biol; 2008 Apr; 28(8):2718-31. PubMed ID: 18285464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
    Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
    Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
    Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells.
    Stefansson OA; Esteller M
    Breast Cancer Res; 2011 May; 13(3):309. PubMed ID: 21672285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.